VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Improving the QoL of patients with multiple myeloma treated with CAR-T therapy

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the quality of life (QoL) of patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) from the CARTITUDE-1 (NCT03548207) and KarMMa (NCT03361748) studies, highlighting the importance of improving the burden of symptoms patients experience after CAR-T therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter